Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD117 + status confers therapeutic sensitivity to Imatinib in patients with Gastrointestinal Stromal Tumor.
The European Medicines Agency (EMA) has authorized imatinib for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).
This statement is based on a regulatory approval from the European Medicines Agency:
Glivec is indicated for the treatment of the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).